Common Stock, par value $0.001
- Symbol
- BMRN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
BioMarin Pharmaceutical Inc.
BMRNNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 2, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2026. The Company’s press release issued on November 2, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.…
Press release in this filing
BioMarin Reports Third Quarter 2026 Financial and Operating Results →Company context
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Current securities
Recent company filings
Registered securities in this filing
BioMarin Pharmaceutical Inc. · 8-K · Filed 2026-11-02
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 2, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2026. The Company’s press release issued on November 2, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Filed exhibits (1)
Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Third Quarter 2026 Financial and Operating Results Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., November 2, 2026 - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026. “BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier …
Open exhibit ↗